It’s one of two major changes to a commonly used abortion medication, alongside new approval to end a pregnancy up to 70 days of gestation, a one-week extension.
GPs can now offer patients greater access to medical abortion and more options for miscarriage care after the Therapeutic Goods Administration (TGA) approved two major changes to a commonly used abortion medication.
MS-2 Step (mifepristone and misoprostol) is now approved for medical abortion up to 70 days’ gestation, extending the previous approved use by seven days, as well as being newly indicated to medically manage missed miscarriage up to 70 days of gestation.
For missed miscarriage, where the embryo or foetus has died but the pregnancy tissue remains inside the uterus and has not yet been passed from the body, the TGA says gestational age is determined by ultrasound.
In both new approvals, safety data did not reveal any concerns and reported side effects were consistent with the known effects of MS-2.
Monash University General Practice Chair and women’s health expert, Professor Danielle Mazza, described the move as ‘highly significant’ for Australian women and GPs.
SOURCE: NewsGP > CLINICAL. by Karen Burge. https://www1.racgp.org.au. /newsgp/clinical/ms-2-step-gets-tga-green-light-for-missed-miscarr, 22 October 2026.